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Abstract
Laboratory assays such as MIC tests assume that antibiotic molecules are stable in the
chosen growth medium - but rapid degradation has been observed for antibiotics
including β-lactams under some conditions in aqueous solution. Degradation rates in
bacterial growth medium are less well known. Here, we develop a ‘delay time bioassay’
that provides a simple way to estimate antibiotic stability in bacterial growth media,
using only a plate reader and without the need to measure the antibiotic concentration
directly. We use the bioassay to measure degradation half-lives of the β-lactam
antibiotics mecillinam, aztreonam and cefotaxime in widely-used bacterial growth media
based on MOPS and Luria-Bertani (LB) broth. We find that mecillinam degradation
can occur rapidly, with a half-life as short as 2 hours in MOPS medium at 37◦C and pH
7.4, and 4-5 hours in LB, but that adjusting the pH and temperature can increase its
stability to a half-life around 6 hours without excessively perturbing growth. Aztreonam
and cefotaxime were found to have half-lives longer than 6 hours in MOPS medium at
37◦C and pH 7.4, but still shorter than the timescale of a typical minimum inhibitory
concentration (MIC) assay. Taken together, our results suggest that care is needed in
interpreting MIC tests and other laboratory growth assays for β-lactam antibiotics,
since there may be significant degradation of the antibiotic during the assay.
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Introduction 1
Antibiotic efficacy is usually quantified by the minimal inhibitory concentration (MIC), 2
or the concentration of antibiotic needed to prevent bacterial growth over 24 hours in a 3
standard laboratory growth medium [1]; the MIC value plays a central role in 4
diagnostic and therapeutic decision-making. When performing an MIC assay, one 5
assumes that the antibiotic does not degrade over the timescale of the assay. Antibiotic 6
stability is also assumed in a host of other bacterial growth assays that are used to 7
determine antibiotic mechanism of action [2–5], interactions between antibiotics [6–9], 8
and evolution of antibiotic resistance [10–14]. 9
Antibiotic degradation in aqueous solution has been extensively studied in the 10
chemical literature [15–19], and it is well-known that, under some conditions, 11
antibiotics can degrade on timescales much shorter than a typical bacterial growth assay. 12
There has been little work, however, on how quickly antibiotics degrade in standard 13
laboratory growth media, such as those used for MIC assays. Here, we develop a 14
‘delay-time bioassay’, based on growth measurements in a plate reader, that allows 15
simple estimation of the rate of antibiotic degradation in bacterial growth media. 16
Importantly, our assay does not require direct measurement of the antibiotic 17
concentration, making it easily usable in labs that are not set up for chemical analysis. 18
Bacterial growth media are chemically complex, since bacterial proliferation requires 19
carbon, nitrogen, phosphorous, iron and a diverse array of micronutrients [20,21]. 20
“Undefined” growth media contain ingredients such as yeast extract, blood or beef 21
extract, whose detailed chemical composition is not known. Luria-Bertani (LB) medium, 22
which consists of water, tryptone, sodium chloride and yeast extract, is a widely-used 23
example. In contrast, “defined” growth media contain known quantities of defined 24
chemical ingredients, and are often pH-buffered, typically at pH 7.2± 0.2. For example, 25
Neidhardt’s rich defined medium [22] consists of a MOPS (3-(N-Morpholino)propane 26
sulfonic acid) pH buffer supplemented with glucose, amino acids, nucleotides and 27
sources of sodium, potassium, chlorine, phosphorous, magnesium, iron, zinc, manganese, 28
bromine, boron, copper, cobalt and molybdenum. It is reasonable to expect that 29
microbiological growth media might affect antibiotic degradation rates; for example, 30
transition metals have been reported to accelerate degradation of β-lactam antibiotics 31
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[23], and Neidhardt’s medium contains Fe2+ at 10 µM, as well as Cu2+ at 10 nM, Mn2+ 32
at 80 nM and Co2+ at 30 nM [22]. Although we are not aware of any quantitative 33
measurements of degradation rates in bacterial growth media, several studies have 34
commented on the phenomenon of ‘regrowth’, in which bacterial cultures show late-time 35
growth in β-lactam-supplemented media after apparent early-time growth suppression 36
[24–27]. This phenomenon could arise from either resistance evolution or degradation of 37
the antibiotic. 38
Our focus here is on degradation rates for β-lactam antibiotics. β-lactams, which 39
inhibit bacterial cell-wall synthesis [28–30], account for the majority of global antibiotic 40
consumption [31]. They are characterised by a β-lactam ring in their molecular 41
structures (Fig 1); clinically relevant classes of β-lactams include penicillin derivatives, 42
cephalosporins, monobactams and carbapenems. The degradation of β-lactam 43
antibiotics in aqueous solution is known to be strongly pH-dependent [32]; β-lactams 44
are degraded via different pathways under acidic versus basic conditions, typically 45
having a U-shaped profile for degradation rate as a function of pH, with maximal 46
stability around pH 4-5 for α-amino β-lactams (e.g. amoxicillin and ampicillin) and 47
around pH 6-7 for β-lactams without a side-chain amino group [33]. As noted above, 48
the degradation rate can also be very sensitive to the presence of transition metal ions 49
[23, 32,33]. 50
Our study focuses on three β-lactams: mecillinam, aztreonam and cefotaxime (Fig 1) 51
which have previously been shown to have stability maxima at pH 4-6 [34–36]. 52
Mecillinam (also known as amdinocillin or FL1060) is an amidinopenicillin that binds 53
selectively to the PBP2 transpeptidase, inhibiting peptidoglycan synthesis during the 54
elongation phase of bacterial growth. Mecillinam is active against Gram-negative 55
bacteria, especially Enterobacteriaciae, and is mainly used to treat urinary tract 56
infections. Mecillinam is somewhat peculiar among β-lactams since its side chain is 57
linked to the core part of the penicillin molecule (the 6-aminopenicillanic acid moiety) 58
via an amidine bond rather than the more usual amide bond (Fig 1A). Its degradation 59
has been shown to be highly pH-sensitive in aqueous solution, with a maximum half-life 60
at pH 5 (at 37◦C) of around 200 hours [16]. Aztreonam (Fig 1B) is a synthetic 61
monobactam that targets peptidoglycan synthesis during cell division by binding to the 62
PBP3 component of the peptidoglycan-synthesizing divisome complex [37]. Aztreonam 63
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is only active against Gram-negative bacteria. It has been found to be most stable at 64
approximately pH 5 in aqueous solution (at 35◦C) [35], and to be more stable than 65
other β-lactams in neutral or acidic conditions. The increased stability is possibly due 66
to reduced strain on the β-lactam ring as it is not attached to a secondary ring (Fig 1B) 67
[35]. Cefotaxime (Fig 1C) is a third-generation cephalosporin β-lactam that targets 68
multiple components of the peptidoglycan synthesis machinery, but with a high affinity 69
for the PBP3 transpeptidase and the bifunctional TPase/TGase PBP1b [38], which are 70
involved in cell division [37]. Cefotaxime is active against a wide range of bacterial 71
species [39] and is used to treat meningitis and septicaemia [40]. The rate of 72
degradation of cefotaxime has been found to be strongly affected by solvolytic, hydrogen 73
ion and hydroxide ion catalysis, with maximum stability at pH 4.5 - 6.5 (at 25◦C) in 74
aqueous solution [36]. 75
Fig 1. Chemical structures of mecillinam, aztreonam and cefotaxime
A: Mecillinam has a characteristic penicillin structure with a fused
beta-lactam-thiazolidine two-ring system [39] and an amidine link to the side chain. B:
Aztreonam has a monobactam structure with no secondary ring attached to the
β-lactam ring, and with an N-SO3H side-chain [35]. C: Cefotaxime has a characteristic
cephalosporin structure with a fused β-lactam-∆3-dihydrothiazine two-ring system [39].
All structures were drawn using the chemfig Latex package.
In this paper, we present the delay-time bioassay and use it to measure degradation 76
times for mecillinam, aztreonam and cefotaxime in MOPS-based media, and for 77
mecillinam in LB. We find that mecillinam is rather unstable in these media, while 78
aztreonam and cefotaxime are more stable, but with half-lives that are still much 79
shorter than the timescale of a typical MIC assay. We also show that changes in pH and 80
temperature can be used to enhance the stability of mecillinam without excessively 81
compromising bacterial growth. 82
Results 83
Growth assays under standard conditions show regrowth 84
Bacteria exposed to β-lactam antibiotics can sometimes show “regrowth”: bacterial 85
growth is initially suppressed by the antibiotic, but at late times the culture starts to 86
grow, eventually reaching a significant cell density [24–27]. Regrowth could be due to 87
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degradation of the antibiotic or to the emergence of resistance in the bacterial 88
population. We observed consistent regrowth in plate reader growth assays for E. coli 89
(strain RJA002, an isogenic fluorescent derivative of MG1655; see Methods) in the 90
presence of mecillinam, aztreonam and cefotaxime (Fig 2 and S3 Fig; see also Methods). 91
After a long period of growth inhibition, the bacterial population started to grow at late 92
times, reaching a significant density by the end of our 24 hour experiments (Fig 2). The 93
length of time before regrowth happened generally increased with the antibiotic 94
concentration (Fig 2). Regrowth was observed on LB medium (S3 Fig C), on MOPS 95
rich defined medium with glucose (MOPSgluRDM; see Methods), and on other 96
MOPS-based media supplemented with glucose or glycerol, in the presence or absence of 97
amino acids and nucleotides (Fig 2 and S3 Fig D-F). 98
Fig 2. Typical growth curves in the presence of β-lactam antibiotics.
Growth curves, measured in the plate reader, for E. coli strain RJA002 (see Methods)
in MOPSgluRDM, in the presence of A: mecillinam, B: cefotaxime and C: aztreonam.
The legends show the antibiotic concentration, in units of µg/ml. Growth curves are
averaged over two replicates. The standard deviation between the replicates is
represented by the shaded area around the lines.
A delay-time assay shows rapid degradation of mecillinam in 99
MOPSgluRDM 100
Motivated by our observations of regrowth in bacterial growth assays, we designed a 101
“delay time bioassay” to measure antibiotic degradation in bacterial growth media. This 102
assay uses a 96-well microplate setup in which replicate wells containing antibiotic are 103
inoculated with bacteria at different times after the start of the experiment. The setup 104
is shown in detail in Fig 3; antibiotic dilutions are set up identically in replicate 105
columns, but different columns are inoculated with E. coli at different times (see 106
Methods for further details). Bacterial growth is monitored throughout the experiment 107
via OD measurements in a plate reader. If the antibiotic is not degraded, then we would 108
expect to see identical sets of growth curves in replicate columns, simply shifted by the 109
inoculation time. However, if the antibiotic is degraded, we expect to observe different 110
growth curves depending on the inoculation time (since the effective concentration of 111
antibiotic at the time of inoculation will be lower for later inoculations). Fig 4 (a) shows 112
that the latter scenario is indeed observed, for E. coli growing in MOPSgluRDM with 113
July 8, 2020 5/26
mecillinam. Here, the dashed lines correspond to wells inoculated 2 hours later than the 114
solid lines, while the colours indicate antibiotic concentration. For example, a 115
comparison between the orange dashed and solid lines shows that growth at the initial 116
concentration of 0.094 µg/ml mecillinam is considerably enhanced for the later 117
inoculation. 118
Fig 3. Plate setup for the delay-time bioassay.
The entire plate is filled with media + antibiotics at the start of the experiment, with
dilution series down the columns as indicated by the shading. The wells shown in yellow
are media-only controls. The blue set of replicate columns are inoculated with bacteria
immediately, and the plate is then incubated in a plate reader with OD measurement.
The green set of columns are inoculated 2 hours later, the pink set of columns a further
2 hours later, etc. If the antibiotic has degraded between inoculations, this will be
reflected in a change in the shape of the measured growth curves for later inoculations.
Fig 4. Degradation half-life of mecillinam is approximately 2 hours in
MOPSgluRDM at pH 7.4, 37◦C.
A: Bioassay measurements: growth curves for E. coli strain RJA002 in MOPSgluRDM
at pH 7.4, 37◦C, for cultures inoculated at time zero (solid lines) and after a delay
period of 2 hours (dashed lines). The different colours correspond to different (initial)
concentrations of mecillinam, as displayed in the legend, in µg/ml. Only a selection of
the concentrations used are displayed to improve the clarity of the plot. B: Bioassay
analysis - the time T at which the growth curves reach a threshold OD of 0.75 is plotted
as a function of the initial antibiotic concentration. The black data correspond to
inoculation at time zero; the blue data to inoculation after a 2 hour delay. The red line
shows the black data, shifted by one unit on the log2 scale; since the blue data falls onto
the red line, the degradation half-life is approximately 2 hours. In both panels A and B,
the data is averaged over two replicates and the shaded areas represent the standard
deviation. C,D: Raman spectroscopy confirms rapid degradation of mecillinam in
MOPSgluRDM. C: Raman spectra for the region between 1000 and 1400 wavenumbers,
recorded at times 0 to 52 hours (time in hours indicated by colour as shown in the
legend). Successive curves are shifted upwards for clarity. D: Relative peak height at
1278 cm−1 as a function of time is fit to an exponential decay, which gives a half-life of
1.3± 0.4 hours. The peak height at 1278 cm−1 was measured relative to the background
spectrum (see Methods).
The delay-time bioassay can be used to estimate the degradation half-life of the 119
antibiotic in the chosen growth medium. For a culture that is inoculated at time tic, the 120
effective antibiotic concentration at the inoculation time will be 121
aeff = a0 exp (− ln 2× tic/td) where a0 is the antibiotic concentration supplied at the 122
start of the experiment and td is the degradation half-life of the antibiotic. We therefore 123
expect the measured growth curve in that well to match the growth curve measured for 124
a well containing concentration aeff , inoculated at time zero. Specifically, for a well set 125
up with a given antibiotic concentration and inoculated at a time that equals the 126
July 8, 2020 6/26
degradation half-life, tic = td, the measured growth curve should match that of a well 127
that was set up with half the concentration, but inoculated at time zero. 128
To simplify our analysis, we chose to characterise the growth curves by a single 129
number: the time T after inoculation at which the OD reaches a threshold value ODt 130
(here taken to be ODt = 0.75). Because the antibiotic inhibits growth, the threshold OD 131
value is reached later for higher antibiotic concentrations. Thus the value of T increases 132
with the effective antibiotic concentration. Plotting T versus the logarithm of the 133
antibiotic concentration (for a fixed inoculation time), we obtain an increasing curve 134
(Fig 4 B; black curve is for inoculation at time zero). Repeating this plot for a later 135
inoculation time, we observe a shift of the entire curve to the right, because the effective 136
antibiotic concentration has decreased during the inoculation delay (Fig 4 B; blue curve 137
is for inoculation at time tic = 2 hours). If the antibiotic concentration axis is plotted 138
on a log2 axis, then an inoculation time equal to the degradation half-life (tic = td) 139
results in a shift of the curve by one unit along the concentration axis. In Fig 4 B, the 140
red curve shows the black data shifted by one unit; if the blue curve matches the red 141
curve, the inoculation time equals the degradation half-life. For mecillinam in 142
MOPSgluRDM at pH 7.4 and 37◦C this is the case for an inoculation time of 2 hours 143
(Fig 4 B); therefore the degradation half-life is approximately 2 hours. 144
Raman spectroscopy confirms rapid degradation of mecillinam 145
in MOPSgluRDM 146
The rapid degradation which we inferred from our delay time bioassay was confirmed by 147
direct measurement of mecillinam degradation using Raman spectroscopy. Raman 148
spectra were measured for samples of mecillinam (at 3 mg/ml) in MOPSgluRDM, and 149
for MOPSgluRDM alone, over a period of 60 hours (see Methods). Fig 4C shows part of 150
the resulting difference spectra (shifted vertically for clarity). A peak at 1278 cm−1, 151
which is believed to arise from the amidine link in the mecillinam molecule (see Fig 1 152
and Methods), clearly disappears over time. This is consistent with evidence that the 153
primary degradation pathway for mecillinam is via hydrolysis of the amidine bond [16]. 154
Fitting an exponential decay function to the peak height (relative to the background 155
spectrum) at 1278 cm−1 as a function of time gives a half-life of 1.3± 0.4 hours 156
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(Fig 4D), consistent with our result from the delay time bioassay. 157
Adjusting pH and temperature can increase mecillinam stability 158
To perform growth assays in the presence of mecillinam, one would like to find 159
conditions under which mecillinam is more stable, while the bacterial growth rate is 160
perturbed as little as possible. While low pH is known to increase the stability of 161
mecillinam in aqueous solution [16], E. coli grows well only in the range pH 6.0 to 162
7.5 [41], and MOPS acts as a pH buffer only in the range pH 6.2 to 8.0 [22]. Therefore 163
we repeated our delay-time bioassay in MOPSgluRDM medium at the lower pH of 6.5. 164
This led to an increase in the half-life of mecillinam, to approximately 4 hours as 165
measured with the delay-time bioassay (S4 Fig A), which was confirmed by Raman 166
spectroscopy (S4 Fig D,E). Since this is still rather short on the timescale of a typical 167
bacterial growth experiment, we sought to further optimise the conditions by decreasing 168
the temperature. Therefore we repeated the delay time assay at 34◦C, for pH 7.4 and 169
pH 6.5. While a decrease in temperature to 34◦C on its own did not significantly 170
increase mecillinam stability (S4 Fig B), combining the temperature decrease with a pH 171
of 6.5 led to a mecillinam half-life of more than six hours (S4 Fig C), while still 172
maintaining an acceptable bacterial growth rate (Table 1). Further decreasing the 173
temperature to 30◦C resulted in a significantly lower bacterial growth rate (Table 1). 174
Table 1. Bacterial growth rates and antibiotic half-lives in MOPSgluRDM at varying temperature and pH
Growth rates were measured by applying a linear fit to the log of the optical density (the number of replicates used is
indicated in the brackets). The antibiotic half-lives measured with the delay-time bioassay are also listed, for mecillinam
(Mec.), cefotaxime (Ctx.) and aztreonam (Azt.).
T (◦C) pH Growth rate (/h) MEC half-life (h) CTX half-life (h) AZT half-life (h)
37 7.4 1.6± 0.4 (3) ∼ 2 > 6 > 6
37 6.5 1.2± 0.1 (10) ∼ 4
30 7.4 0.97± 0.05 (4)
34 7.4 1.3± 0.1 (3) ≥ 2
34 6.5 1.4± 0.2 (7) > 6
37 7.0 (LB) 1.5± 0.2 (4) 4− 6
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Mecillinam is somewhat more stable in LB medium than in 175
MOPS 176
Luria-Bertani (LB) medium is an undefined growth medium that is widely used for 177
bacterial growth experiments. We used the delay-time bioassay to determine the 178
stability of mecillinam in LB medium at 37◦C. The pH of the medium was measured to 179
be 7.0 at the start of the experiment (although since LB does not contain a pH buffer 180
we expect the pH to decrease during the experiment due to bacterial growth). Our 181
results show that mecillinam has a half-life of 4-6 hours in LB at 37◦C (S5 Fig). The 182
fact that mecillinam appears to be more stable in LB than in our MOPSgluRDM 183
experiments at pH 7.4 may arise from the somewhat lower pH of the LB medium [16]; 184
another significant factor might be a lower concentration of transition metal ions, which 185
have been found to destabilise β-lactams [32,33]. 186
Aztreonam and cefotaxime have longer half-lives than 187
mecillinam in MOPSgluRDM 188
To demonstrate the generality of the delay time assay, we used it to estimate 189
degradation rates of two other β-lactam antibiotics in MOPSgluRDM at pH 7.4 and 190
37◦C. Aztreonam is a monobactam that selectively targets the division transpeptidase 191
PBP3 [42], while cefotaxime is a third-generation cephalosporin that targets multiple 192
components of the cell division machinery [38]. Both these antibiotics have qualitatively 193
similar effects on the growth dynamics of E. coli, with a concentration-dependent period 194
of growth inhibition, followed by regrowth of the bacterial population (Fig 5A). 195
For aztreonam, the delay time assay showed degradation over the course of the 196
experiment, but with a half-life greater than six hours (Fig 5B). This is consistent with 197
previous suggestions that monobactams are more stable than other β-lactams (except 198
under alkaline conditions), possibly because of reduced strain on the β-lactam ring due 199
to the absence of a secondary ring (Fig 1) [35]. 200
For cefotaxime, the characteristic shape of the antibiotic-inhibited growth curve (i.e. 201
a period of inhibition followed by regrowth) was only observed within a rather narrow 202
concentration range (0.016 to 0.125µg/ml). For smaller concentrations of cefotaxime, 203
growth was not inhibited, while for larger concentrations, growth was completely 204
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Fig 5. Aztreonam and cefotaxime have half-lives longer than 6 hours in
MOPSgluRDM at pH 7.4 and 37◦C.
A,B: Delay-time bioassay for aztreonam. A: Time-shifted growth curves. Solid lines
show results for immediate inoculation; dashed lines are for inoculation with a 4 hour
delay. The aztreonam concentrations are listed in the legend with units of µg/ml. B:
Analysis (plots of time to reach OD threshold of 0.75). The red curve shows the black
curve (immediate inoculation) shifted by 1 log2 unit. The blue curve corresponds to
inoculation after a 2 hour delay, the green curve a 4 hour delay and the teal curve a 6
hour delay. Since the curves for delayed inoculation of 4h and 6h (green and teal curves)
do not reach the red curve, the half-life is longer than 6 hours. C,D: Delay-time
bioassay for cefotaxime. C: Time-shifted growth curves. Solid lines show results for
immediate inoculation; dashed lines are for inoculation with a 2 hour delay. The
cefotaxime concentrations are listed in the legend with units of µg/ml. D: Analysis
(plots of time to reach OD threshold of 0.75). The red curve shows the black curve
(immediate inoculation) shifted by 1 log2 unit. The blue curve corresponds to
inoculation after a 2 hour delay, the green curve a 4 hour delay and the teal curve a 6
hour delay. Since the curves for delayed inoculation of 4h and 6h (green and teal curves)
do not reach the red curve, the half-life is longer than 6 hours.
inhibited (no regrowth was observed) (S6 Fig). Because the delay time bioassay relies 205
on matching the shapes of growth curves for different antibiotic concentrations, the 206
analysis could only be performed within this rather narrow concentration range where 207
the growth curves were qualitatively similar (Fig 5C). Nevertheless, our analysis showed 208
clearly that, although cefotaxime does degrade during our experiment, its degradation 209
half-life is longer than 6 hours (Fig 5D - the curve for the 6 hour inoculation delay lies 210
to the left of the zero-delay curve shifted by one log2 unit). 211
Discussion 212
Microbiological growth assays, such as the MIC assay, play a central role in the 213
diagnosis and treatment of bacterial infections. These assays usually assume that the 214
antibiotic in question is stable over the timescale of the assay, typically 24 hours. Our 215
results call this assumption into question, since we find that the β-lactam antibiotics 216
tested here (mecillinam, aztreonam and cefotaxime) degrade on faster timescales than 217
24 hours in widely used bacterial growth media, with mecillinam being especially prone 218
to rapid degradation, although its stability can be somewhat enhanced by adjusting the 219
pH and temperature. Therefore our work suggests that care is needed in interpreting 220
MIC tests and other laboratory growth assays for β-lactam antibiotics, since there may 221
be significant degradation of the antibiotic during the assay. While rapid degradation of 222
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β-lactams in aqueous solution has been widely reported in the chemical literature, we 223
believe that our study is the first to report this in standard microbiological growth 224
media. 225
The delay-time bioassay which we develop here is easy to implement in a 226
microbiological lab, requiring only a 96-well plate reader capable of shaking incubation 227
and optical density measurement. The underlying principle of the assay is very simple: 228
replicate wells containing antibiotic plus media are incubated in the plate reader for 229
different amounts of time prior to inoculation, and the shape of the resulting bacterial 230
growth curve is used to infer the effective concentration of the antibiotic in a given well 231
at the time of inoculation. To simplify our analysis, we defined a threshold optical 232
density and plotted the time taken to reach this threshold versus the logarithm of the 233
(initial) antibiotic concentration: this provides a simple way to extract the degradation 234
half-life. This analysis works for the three β-lactam antibiotics which we studied here, 235
because of the ‘regrowth’ phenomenon: bacterial populations typically eventually reach 236
a high density in these antibiotics, after an initial period of growth suppression that 237
depends on the antibiotic concentration. For cefotaxime, where this characteristic 238
growth curve was only observed within a narrow concentration range, the analysis was 239
somewhat more challenging but the method nevertheless allowed us to place a lower 240
bound on the degradation time. 241
For other classes of antibiotic, we would expect different characteristic forms for the 242
growth curves, potentially making the definition of a threshold optical density more 243
difficult. However, the general principle of matching growth curves for later inoculation 244
times with those of reduced initial antibiotic concentrations still holds. Our assay also 245
relies on the principle that replicate growth curves are expected to be very similar. This 246
is the case for the β-lactams that we study here (Figs 4, 5) but variability between 247
replicate growth curves might be an issue for some other antibiotics, at concentrations 248
close to the MIC. In this case one might need to perform averages over larger numbers 249
of replicates, inoculated at the same time. 250
The three antibiotics studied here, mecillinam, aztreonam and cefotaxime, represent 251
different β-lactam sub-classes and show differing stability, with mecillinam being 252
particularly unstable. However, we find that all of them degrade over timescales that 253
are significantly shorter than a typical bacterial growth assay, suggesting that MIC and 254
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other assays should be interpreted carefully. In particular, our results suggest that the 255
characteristic form of bacterial growth curves in the presence of β−lactams, in which 256
initial growth suppression is followed by concentration-dependent “regrowth”, may occur 257
because, over time, the antibiotic degrades below a threshold concentration, allowing 258
surviving (antibiotic-sensitive) cells to proliferate. In this simplified picture, whether or 259
not growth is observed in a MIC assay would depend on whether the assay duration was 260
long enough for the concentration to decay below the growth threshold. Our results hint, 261
then, that apparent MIC values measured for β-lactams may reflect some convolution of 262
the study design (duration of assay vs degradation time) with the physiological response 263
of the bacteria to the antibiotic. Since the antibiotic dosage regimen in a clinical 264
scenario may be quite different to that in a microbiological assay (e.g. antibiotic may be 265
administered continuously through an IV line), our results suggest that care is needed in 266
translating the results of MIC assays for β-lactams into clinical scenarios. 267
While our study focused on standard microbiological growth media (MOPS-based 268
media and LB), it would also be interesting to measure antibiotic stability in media that 269
are more typical of infections, such as urine or tissue culture medium. Recent work 270
suggests that antibiotic susceptibility can be significantly altered in tissue culture 271
medium compared to standard bacterial growth media [43]; it would be interesting to 272
know if the same is true for antibiotic degradation. If β-lactam degradation is indeed 273
rapid under conditions that are realistic of clinical infections, this could be a significant 274
factor in determining antibiotic dosage protocols. 275
Materials and methods 276
Antibiotics 277
Antibiotic stock solutions were as follows: mecillinam (Sigma-Aldrich), 3 mg/ml in 278
sterile water; cefotaxime (Fisher-Scientific), 10 mg/ml in sterile water; aztreonam 279
(Cambridge Bioscience), 25 mg/ml in DMSO. Antibiotic solutions prepared by dilution 280
of the stock solutions in water were filter sterilised using 0.22 µm membrane filters 281
(MillexGP). 282
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Bacterial strains 283
MIC (minimum inhibitory concentration) assays to determine the antibiotic 284
concentrations of interest were performed using Escherichia coli strain MG1655. 285
Bioassay measurements were performed using E. coli strain RJA002 [44], which is a 286
derivative of MG1655 carrying a chromosomal yellow fluorescent protein 287
(YFP)/chloramphenicol resistance reporter. The reporter is under the control of the 288
constitutive λPR promoter, and was made by P1 transduction from strain MRR of 289
Elowitz et al. [45]. Growth curves for RJA002 in the presence of the relevant β-lactam 290
antibiotics were found to be indistinguishable from those obtained for the wild-type 291
MG1655 strain (see supplementary material S3 Fig A and B). 292
Microbiological growth media 293
Luria-Bertani (LB) medium was made in-house using components purchased from 294
Fisher-Scientific, and its pH was 7.0. MOPS rich defined medium with glucose (referred 295
to here as MOPSgluRDM) is a version of Neidhardt’s MOPS defined medium 296
supplemented with nucleotides, amino acids and vitamins [22]. It was prepared in-house 297
following the protocol developed by the E. coli Genome Project (University of 298
Wisconsin) [46] to make EZ Rich Defined Medium (RDM). In this protocol, EZ RDM is 299
assembled from four components (10x MOPS base medium, 0.132M K2HPO4, 10x 300
ACGU (containing nucleotides) and 5x EZ supplement (containing amino acids and 301
vitamins) - for details see below). Each component was made, sterilised and stored as 302
single use aliquots. The complete medium was assembled just prior to use. Carbon 303
source was also added at this stage. The in-house MOPS media was compared with 304
commercially available MOPS media (Teknova), and found to support the same growth 305
dynamics and doubling times for E. coli MG1655 in MOPSgluRDM (doubling time 306
34± 1 minutes) as well as in MOPSgluMIN (MOPS media without added amino acids, 307
nucleotides or vitamins; doubling time 103± 2 minutes) (S1 Fig). 308
The MOPS base medium consisted of: MOPS buffer (40mM, pH 7.4 with KOH), 309
4mM Tricine (source of iron), 10µM iron sulphate, 9.5mM ammonium chloride, 310
0.276mM potassium sulphate, 0.5µM calcium chloride, 0.525mM magnesium chloride, 311
50mM sodium chloride, 29nM ammonium molybdate, 4µM boric acid, 0.3µM cobalt 312
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chloride, 96nM copper sulphate, 0.812µM manganese chloride, 98nM zinc sulphate, 313
1.32mM dipotassium phosphate, sterile H2O and K2HPO4. The resulting MOPS growth 314
medium has a buffering capacity from pH 6.2 to 8.0 [22] and was supplemented with 315
glucose to a final w/v of 2%. The EZ supplement consists of the following amino acids 316
(concentrations listed are those in the complete MOPSgluRDM media): 0.8mM alanine, 317
5.2mM arginine, 0.4mM asparagine, 0.4mM aspartic acid, 0.1mM cysteine, 0.6mM 318
glutamic acid, 0.6mM glutamine, 0.8mM glycine, 0.2mM histidine, 0.4mM isoleucine, 319
0.8mM leucine, 0.04mM lysine, 0.2mM methionine, 0.4mM phenylalanine, 0.4mM 320
proline, 10mM serine, 0.4mM threonine, 0.1mM tryptophan, 2mM tyrosine, 0.6mM 321
valine. Vitamins are added to the EZ supplement: namely thiamine HCL, calcium 322
pantothenate, p-aminobenzoic acid, p-hydroxybenzoic acid, and 2,3 –dihydroxybenzoic 323
acid each at a final concentration of 10µM. The ACGU supplement consists of 0.2mM 324
adenine, 0.2mM cytosine, 0.2mM uracil, 0.2mM guanine. 325
In this work, where needed, MOPSgluRDM was adjusted to pH 6.5 by gradually 326
adding 1M HCl. The final volume of 1M HCl added was 2-3% of the total volume. 327
Raman spectroscopy 328
Raman spectra were measured for samples of mecillinam in MOPSgluRDM at pH 7.4 or 329
6.5, at a concentration of 3 mg/ml. Measurements were taken at various timepoints over 330
several days. One to two independent spectra were obtained at each timepoint. Spectra 331
were also measured for samples of MOPSgluRDM only; these were obtained as averages 332
of three independent measurements. The Raman spectra were obtained using a high 333
contrast Coderg triple spectrometer set at a resolution between five and six 334
wavenumbers across the recorded spectral region. The excitation source was an argon 335
ion laser operating at 488 nm with plasma lines removed by a prism spectrometer to 336
produce approximately 1W pure laser light though the cell. The sample cuvette was 337
fitted into a copper block with 4 holes at right angles to let the beam through and allow 338
right-angle Raman collection (S2 Fig). The copper block was temperature controlled to 339
better than 0.1◦C with a Eurotherm controller in P.I.D. mode and maintained at 37◦C. 340
To reduce the time taken per scan, allowing better time resolution, spectra were 341
recorded only in the range 0-1800cm−1. Following data acquisition, difference spectra 342
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were obtained by subtracting the (averaged) MOPSgluRDM spectra for a given 343
timepoint from those of the mecillinam-MOPSgluRDM samples at the same timepoint, 344
using Origin software. The resulting difference spectra were then cross-referenced with 345
the standard mecillinam spectrum available in Biorad’s KnowItAll software. Using peak 346
height relative to the background signal (10-20 wavennumbers away from the peak), 347
peaks were identified which showed clear decay over time. These peaks were assigned 348
using Biorad’s KnowItAll software, combined with a literature survey [47–55]. One peak 349
of interest was determined (see Fig 4C): 1278 cm−1 (thought to be due to twisting of 350
C-N-C [47], or twisting of the CH2 group [55])). The peak at 1278 cm
−1 was identified 351
as important as a Biorad’s KnowItAll database search of possible mecillinam 352
degradation products (e.g. penicilloic acid [16]) demonstrated that these degradation 353
products generally are not expected to have a peak at 1278 cm−1. In summary this 354
peak is thought to be linked to the amidine bond found in mecillinam (Fig 1 A). The 355
background signal used for the 1278 cm−1 peak was the average signal from 1261 - 356
1266 cm−1. 357
Plate reader growth 358
Bacterial growth measurements were performed in a Fluostar Optima plate reader, with 359
double orbital shaking at 600rpm, using Greiner flat-bottomed 96-well plates. Lids were 360
used to reduce evaporation over the course of long experiments. The lids were taped 361
onto the plate using small strips of autoclave tape on each side, allowing air to flow while 362
preventing the production of plastic dust which occurs for shaken plates with unsecured 363
lids. The optical density (OD) of each well in the plate was measured approximately 364
every five minutes. The optical density data from the plate reader was analysed using 365
custom Python code to determine growth rates and averages across replicates. A typical 366
plate setup is shown in Fig 3. Growth rates were extracted from plots of the natural log 367
of the optical density. A linear fit over a window of 10 datapoints (or 20 for very slow 368
growth) was used. This window was moved along the log(OD) curve one datapoint at a 369
time, with a linear fit determined at each step i.e. a gradient and residual was found for 370
each window. The best-fit maximal growth rate is taken as the highest gradient with 371
the lowest residual. This is necessary as a low gradient with a good linear fit (low 372
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residual) is likely to be from the stationary phase portion of the growth curve 373
MIC assays 374
Minimum inhibitory concentrations (MIC) were measured via a micro-dilution 375
protocol [56] using a Fluostar Optima plate reader in LB medium. For each antibiotic, 376
the concentration range used in the MIC assay was determined from the MIC database 377
on the EUCAST (European Committee on Antimicrobial Susceptibility Testing) website 378
(Table 2). Each MIC assay was performed in duplicate columns of a 96-well plate, with 379
each well containing 190 µl of antibiotic-supplemented growth media. Within each 380
column, the top row contained the highest concentration of antibiotic (generally four 381
times the EUCAST MIC value), and the antibiotic concentration was diluted 2-fold 382
down the column, with the bottom well containing no antibiotic. Each well was then 383
inoculated with 10 µl of E. coli MG1655 that were growing exponentially at OD∼0.2. 384
After inoculation the plate was incubated for 22-24 hours at at 37◦C with orbital 385
shaking at 600 rpm (in the plate reader). The MIC was determined by visual inspection 386
of the turbidity of the wells after incubation: the MIC was taken to be the lowest 387
concentration that showed no turbidity in either of the duplicate wells [56]. If the 388
antibiotic concentration range obtained using the EUCAST database did not result in 389
an MIC value (i.e. if all wells showed growth), then the concentration range was shifted 390
and the assay repeated until an MIC value was obtained. In each plate, at least one 391
column contained only growth medium as a control for contamination. The MICs 392
measured in this work are also listed in Table 2, and were generally slightly higher than 393
those reported in the EUCAST database. This could be due to differences in 394
measurement protocol e.g. inoculation size used (we note that EUCAST MIC data are 395
aggregated from various sources which may use slightly different protocols). 396
Table 2. MIC values for the antibiotics used in this work
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Delay-time bioassay 397
The delay-time bioassay measures antibiotic degradation rates by sequential bacterial 398
inoculation of identically-prepared wells in a 96-well microplate, at regular time intervals. 399
It is an adaptation of the MIC protocol that takes advantage of the fact that if an 400
antibiotic is degrading over time we should observe a change in the growth dynamics 401
between sequential inoculations. For example, if an antibiotic has a degradation half-life 402
of two hours, and a bacterial inoculum is added two hours after the plate is filled with 403
antibiotic, at what was initially a concentration of X µg/ml, the culture should exhibit 404
the growth dynamics normally associated with a concentration of X/2 µg/ml. 405
In the delay-time bioassay, a 96-well plate is set up as in Fig 3: 6 columns of the 406
plate are filled with 190 µl of antibiotic-supplemented growth medium per well. Within 407
each column, the antibiotic concentration is diluted 2-fold in successive rows, and the 408
bottom row contains no antibiotic. The starting concentration is set at four times the 409
measured MIC (Table 2), therefore the third row is at the MIC. At least one additional 410
column contains growth medium only, as a control for contamination. At the start of 411
the experiment, the first 2 columns are inoculated with 10µl of a “starter” culture of 412
E. coli (strain RJA002), in the exponential phase of growth at OD600 ∼0.2. Following 413
inoculation, the OD600 of the inoculated wells is ∼0.01 and the final volume is 200 µl. 414
The plate is then incubated in the plate reader at 37◦ C, with 600rpm double orbital 415
shaking, and OD measurements are performed at time intervals of ∼5 min. At the same 416
time, the starter culture is diluted such that it is expected to again reach OD∼0.2 after 417
a period of 2 hours. After the plate and starter culture have been incubated for 2 hours, 418
the plate is removed from the plate reader, the next 2 columns are inoculated from the 419
starter culture, the starter culture is again diluted, and incubation (with plate reader 420
OD measurement) is continued. This process is repeated until all wells have been 421
inoculated. The plate is then incubated in the plate reader, with OD measurement, for 422
a further 16-18 hours. 423
Following data acquisition, a background subtraction is performed for each well, 424
using the first OD reading (time zero) as a proxy for the background OD (note that the 425
inoculum size is small enough to be below the plate reader’s detection threshold). 426
Background-subtracted OD measurements for replicate wells are then averaged, and 427
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each set of data is time-shifted by its inoculation time, to produce a growth curve 428
starting from the time of inoculation. This results in a set of 6 growth curves, 429
corresponding to bacterial growth in medium that has been pre-incubated for 0, 2, 4, 6, 430
8 or 10 hours prior to inoculation (see Fig 4A). If the antibiotic does not degrade, these 431
curves would be identical; antibiotic degradation will cause the curves to shift with the 432
time of pre-incubation, since the antibiotic concentration experienced by the bacteria is 433
lower than the initially added concentration. 434
To quantify the extent of any shift in the growth curves, we define a threshold OD 435
value (ODt=0.75 in this work), and measure the time T after inoculation at which this 436
threshold is reached. This time T increases with the antibiotic concentration, since the 437
antibiotic inhibits bacterial growth. (Fig 4B). We plot a curve of T versus 438
log2(antibiotic concentration), for each inoculation time. In this plot, degradation of the 439
antibiotic results in a change in the effective antibiotic concentration experienced by the 440
bacteria, and thus a shift to the right of the plot. The antibiotic half-life is the 441
inoculation delay required to shift the curve by one unit on the logarithmic 442
concentration axis (Fig 4B). 443
Acknowledgments 444
We thank S. Lucas Black for making strain RJA002 and Meriem El Karoui and 445
Bar lomiej Waclaw for helpful discussions. 446
References
1. Andrews JM. Determination of minimum inhibitory concentrations. J
Antimicrob Chemother. 2001;48(Suppl. S1):5–16.
2. Nonejuie P, Burkart M, Pogliano K, Pogliano J. Bacterial cytological profiling
rapidly identifies the cellular pathways targeted by antibacterial molecules.
PNAS. 2013;110(40):16169–16174.
3. Cushnie TPT, O’Driscoll NH, Lamb AJ. Morphological and ultrastructural
changes in bacterial cells as an indicator of antibacterial mechanism of action.
Cell Mol Life Sci. 2016;73(23):4471–4492.
July 8, 2020 18/26
4. Brudzynski K, Sjaarda C. Antibacterial compounds of canadian honeys target
bacterial cell wall inducing phenotype changes, growth inhibition and cell lysis
that resemble action of β-lactam antibiotics. PLoS ONE. 2014;9(9).
5. Spratt BG. The mechanism of action of mecillinam. J Antimicrob Chemother.
1977;3:13–19.
6. Ocampo PS, La´za´r V, Papp B, Arnoldini M, Zur Wiesch PA, Busa-Fekete R,
et al. Antagonism between bacteriostatic and bactericidal antibiotics is prevalent.
Antimicrob Agents Chemother. 2014;58(8):4573–4582.
7. Nguyen C, Zhou A, Khan A, Miller JH, Yeh P. Pairwise antibiotic interactions in
Escherichia coli : triclosan, rifampicin and aztreonam with nine other classes of
antibiotics. J Antibiot. 2016; p. 1–7.
8. Bollenbach T, Quan S, Chait R, Kishony R. Nonoptimal microbial response to
antibiotics underlies suppressive drug interactions. Cell. 2009;139(4):707–718.
9. Bollenbach T, Kishony R. Resolution of gene regulatory conflicts caused by
combinations of antibiotics. Mol Cell. 2011;42(4):413–425.
10. Toprak E, Veres A, Michel Jb, Chait R, Hartl DL, Kishony R. Evolutionary
paths to antibiotic resistance under dynamically sustained drug selection. Nature
Genetics. 2012;44(1):101–105.
11. Reding-Roman C, Hewlett M, Duxbury S, Gori F, Gudelj I, Beardmore R. The
unconstrained evolution of fast and efficient antibiotic-resistant bacterial genomes.
Nat Ecol Evol. 2017;1:0050.
12. Artemova T, Gerardin Y, Dudley C, Vega NM, Gore J. Isolated cell behavior
drives the evolution of antibiotic resistance. Mol Syst Bio. 2015;11(822):1–11.
13. Chevereau G, Dravecka´ M, Batur T, Guvenek A. Quantifying the determinants
of evolutionary dynamics leading to drug resistance. PLOS Biology.
2015;13(11):1–18.
14. Tenaillon O, Barrick JE, Ribeck N, Deatherage DE, Blanchard JL, Dasgupta A,
et al. Tempo and mode of genome evolution in a 50,000-generation experiment.
Nature. 2016;536:165–170.
July 8, 2020 19/26
15. Neu HC. Mecillinam, a novel penicillanic acid derivative with unusual activity
against Gram-negative bacteria. Antimicrob Agents Chemother.
1976;9(5):793–799.
16. Baltzer B, Lund F, Rastrup-Andersen N. Degradation of mecillinam in aqueous
solution. J Pharm Sci. 1979;68(10):1207–1215.
17. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM.
Comparative stability studies of antipseudomonal β-lactams for potential
administration through portable elastomeric pumps (home therapy for cystic
fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob
Agents Chemother. 2002;46(8):2327–2332.
18. Vella-Brincat JWA, Begg EJ, Gallagher K, Kirkpatrick CMJ, Zhang M,
Frampton C, et al. Stability of benzylpenicillin during continuous home
intravenous therapy. J Antimicrob Chemother. 2004;53(4):675–677.
19. Samara E, Moriarty TF, Decosterd LA, Richards RG, Gautier E, Wahl P.
Antibiotic stability over six weeks in aqueous solution at body temperature with
and without heat treatment that mimics the curing of bone cement. Bone Jt Res.
2017;6(5):296–306.
20. Lugtenberg B, Peters R, Bernheimer H, Berendsen W. Influence of cultural
conditions and mutations on the composition of the outer membrane proteins of
Escherichia coli . Mol Gen Genet. 1976;147:251–262.
21. Neidhardt FC, Ingraham JL, Schaechter M. Physiology of the Bacterial Cell.
Sunderland, Massachusetts: Sinauer Associates, Inc.; 1990.
22. Neidhardt FC, Bloch PL, Smith DF. Culture medium for enterobacteria. J
Bacteriol. 1974;119(3):736–747.
23. Deshpande AD, Baheti KG, Chatterjee NR. Degradation of β-lactam antibiotics.
Curr Sci. 2004;87(12):1684–1695.
24. Chevereau G, Bollenbach T. Systematic discovery of drug interaction
mechanisms. Mol Syst Bio. 2015;11(4):807.
July 8, 2020 20/26
25. Greenwood D, O’Grady F. FL 1060: a new beta-lactam antibiotic with novel
properties. J Clin Pathol. 1973;26(1):1–6.
26. Molina-Quiroz RC, Mun˜oz-Villagra´n CM, de la Torre E, Tantalea´n JC, Va´squez
CC, Pe´rez-Donoso JM. Enhancing the antibiotic antibacterial effect by sub lethal
tellurite concentrations: Tellurite and cefotaxime act synergistically in
Escherichia coli . PLoS ONE. 2012;7(4):1–6.
27. Greenwood D, Eley A. A turbidimetric study of the responses of selected strains
of Pseudomonas aeruginosa to eight antipseudomonal β-lactam antibiotics. J
Infect. 1982;145(1):110–117.
28. Donadio S, Sosio M. Inhibitors of Cell-Wall Synthesis. In: Gualerzi CO, Brandi
L, Fabretti A, Pon CL, editors. Antibiotics: Targets, Mechanisms and Resistance.
first edit ed. Wiley-VCH Verlag CmbH & Co. KGaA; 2014. p. 133–149.
29. Demain AL, Sanchez S. Microbial drug discovery: 80 Years of progress. J
Antibiot. 2009;62(1):5–16.
30. Bugg TDH, Braddick D, Dowson CG, Roper DI. Bacterial cell wall assembly:
Still an attractive antibacterial target. Trends Biotechnol. 2011;29(4):167–173.
31. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al.
Global increase and geographic convergence in antibiotic consumption between
2000 and 2015. PNAS. 2018;115(15):E3463–E3470.
32. Van Krimpen PC, Van Bennekom WP, Bult A. Penicillins and cephalosporins
Physicochemical properties and analysis in pharmaceutical and biological
matrices. Pharm Weekbl [Sci]. 1987;9(1):1–23.
33. Hou JP, Poole JW. β-lactam antibiotics: Their physicochemical properties and
biological activities in relation to structure. J Pharm Sci. 1971;60:503–532.
34. Tybring L. Mecillinam (FL 1060), a 6β-amidinopenicillanic acid derivative: In
vitro evaluation. Antimicrob Agents Chemother. 1975;8(3):266–270.
35. Mendez R, Alemany T, Martin-Villacorta J. Stability in aqueous solution of two
monocyclic beta-lactam antibiotics: Aztreonam and Nocardicin A. Chem Pharm
Bull. 1992;40(12):3222–3227.
July 8, 2020 21/26
36. Berge SM, Henderson NL, Frank MJ. Kinetics and mechanism of degradation of
cefotaxime sodium in aqueous solution. J Pharm Sci. 1983;72:59–63.
37. Egan AJF, Vollmer W. The physiology of bacterial cell division. Ann N Y Acad
Sci. 2013;1277(1):8–28.
38. Kocaoglu O, Carlson EE. Profiling of β-lactam selectivity for penicillin-binding
proteins in Escherichia coli strain DC2. Antimicrob Agents Chemother.
2015;59(5):2785–2790.
39. Greenwood D, Pearson N, Eley A, O’Grady F. Comparative in vitro activities of
cefotaxime and ceftizoxime (FK749): New cephalosporins with exceptional
potency. Antimicrob Agents Chemother. 1980;17(3):397–401.
40. Consortti LP, Salgado HRN. A critical review of analytical methods for
quantification of Cefotaxime. Crit Rev Anal Chem. 2017;47(4):359–371.
41. Presser KAA, Ratkowsky DA, Ross T. Modelling the growth rate of Escherichia
coli as a function of pH and lactic acid concentration. Appl Environ Microbiol.
1997;63(6):2355–2360.
42. Pisabarro AG, Prats R, Va´quez D, Rodr´ıguez-Te´bar A. Activity of
penicillin-binding protein 3 from Escherichia coli . J Bacteriol.
1986;168(1):199–206.
43. Kumaraswamy M, Lin L, Olson J, Sun CF, Nonejuie P, Corriden R, et al.
Standard susceptibility testing overlooks potent azithromycin activity and
cationic peptide synergy against MDR Stenotrophomonas maltophilia. J
Antimicrob Chemother. 2016;71(5):1264–1269.
44. Lloyd DP, Allen RJ. Competition for space during bacterial colonization of a
surface. J R Soc Interface. 2015;12(110).
45. Elowitz M, Levine AJ, Siggia ED, Swain PS. Stochastic gene expression in a
single cell. Science. 2002;297(1):1183–1187.
46. EZ Rich Defined Medium protocol. University of Wisconsin (USA); 2019.
https://www.genome.wisc.edu/resources/protocols/ezmedium.htm.
July 8, 2020 22/26
47. Jiang X, Qin X, Yin D, Gong M, Yang L, Zhao B, et al. Rapid monitoring of
benzylpenicillin sodium using Raman and surface enhanced Raman spectroscopy.
Spectrochim Acta A. 2015;140:474–478.
48. Hobro AJ, Rouhi M, Blanch EW, Conn GL. Raman and Raman optical activity
(ROA) analysis of RNA structural motifs in Domain I of the EMCV IRES.
Nucleic Acids Research. 2007;35(4):1169–1177.
49. Small EW, Peticolas WL. Conformational dependence of the Raman scattering
intensities from polynucleotides. III. Order disorder changes in helical structures.
Biopolymers. 1971;10(8):1377–1418.
50. Rizzuto T. Technical application note: The Raman spectrum of water. 2017;.
51. Heidari Torkabadi H, Bethel CR, Papp-Wallace KM, De Boer PAJ, Bonomo RA,
Carey PR. Following drug uptake and reactions inside Escherichia coli cells by
Raman microspectroscopy. Biochemistry. 2014;53(25):4113–4121.
52. Zhang L, Jin Y, Mao H, Zheng L, Zhao J, Peng Y, et al. Structure-selective
hot-spot Raman enhancement for direct identification and detection of trace
penicilloic acid allergen in penicillin. Biosens Bioelectron. 2014;58:165–171.
53. Iliescu T, Baia M, Pavel I. Raman and SERS investigations of potassium
benzylpenicillin. J Raman Spectrosc. 2006;37(1-3):318–325.
54. Spectroscopy IR, Edition S. Biochemical and Medical Applications. In:
Introductory Raman Spectroscopy, Second Edition. 1. Elsevier Science (USA);
2003. p. 295–324.
55. Sumayya A, Panicker CY, Varghese HT, Harikumar B. Vibrational spectroscopic
studies and AB inition calculations of l-glutamic acid 5-amide. RJC Rasayan J
Chem. 2008;1(3):548–555.
56. CLSI. Performance standards for antimicrobial susceptibility testing;
twenty-second informational supplement. vol. 32; 2013.
July 8, 2020 23/26
Supporting information
• S1 Fig: Comparison of growth dynamics for in-house and Teknova MOPS media.
• S2 Fig: Raman spectroscopy set-up.
• S3 Fig: Growth curves showing regrowth for E. coli MG1655 and RJA002 in the
presence of mecillinam or cefotaxime on various media.
• S4 Fig: Delay time assay and Raman spectra for mecillinam in MOPSgluRDM at
shifted pH and temperature.
• S5 Fig: Delay time bioassay results for mecillinam in LB at 37◦ C and pH 7.
• S6 Fig: Growth curves for cefotaxime in MOPSgluRDM at 37◦ C and pH 7.
S1 Fig. Comparison of growth dynamics for in-house and Teknova MOPS
media. Plate reader growth curves for E. coli MG1655 in both MOPSgluMIN and
MOPSgluRDM. OD refers to the optical density at 600 nm. The error bars represent
the standard error of the mean between the 11 replicates for each condition.
S2 Fig. Raman spectroscopy set-up.
Diagram of the light path used to obtain the Raman spectra from a top-down
perspective. The ⊗ and  symbols represent the electric wave vector going into, and
coming out of, the page, respectively. The sample is held in a cuvette within a copper
block, with four holes, through which the scattered laser light can be collect (and
amplified) perpendicular to the incident light. The copper block is also used to achieve
temperature control of the sample.
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S3 Fig. Growth curves showing regrowth for E. coli MG1655 and RJA002
in the presence of mecillinam or cefotaxime on various media.
A, B: Identical population dynamics are observed for E. coli MG1655 (solid lines) and
RJA002 (dashed lines). A: Population dynamics of MG1655 and RJA002 in LB with
mecillinam. B: Population dynamics of MG1655 and RJA002 in MOPSgluRDM with
cefotaxime. C: Regrowth is observed for E. coli RJA002 on LB growth medium at
around 1000 minutes for mecillinam concentrations of 0.375µg/ml up to 6µg/ml. D:
Regrowth is observed for E. coli MG1655 on MOPSgluCAA at around 400 minutes for
mecillinam concentrations of 0.094µg/ml-0.375µg/ml. E: Regrowth is observed for
E. coli MG1655 on MOPSglycRDM (glyc signifies 20% w/v glycerol is used instead of
glucose) after 600 minutes for mecillinam concentrations of 0.094µg/ml-0.75µg/ml, F:
Regrowth is observed for E. coli MG1655 on MOPSglycCAA after 800 minutes for
mecillinam concentrations of 0.094µg/ml-0.375µg/ml. In every panel the mecillinam
concentrations displayed are listed in the legend with units of µg/ml, and the shading
represents the standard deviation between the averaged 2-4 replicates.
S4 Fig. Delay time assay and Raman spectra for mecillinam in
MOPSgluRDM at shifted pH and temperature
A, B, C: Plots of time to reach OD threshold of 0.75. The red curve corresponds to the
black curve (immediate inoculation) shifted by 1 log2 unit. The blue and green curves
are for inoculations delayed by 2, 3, 4 or 6 hours. Shading around the lines is
representative of the standard deviation between the two averaged replicates. A:
MOPSgluRDM at 37◦ and pH 6.5. As the green curve (inoculation delayed by 4 hours)
coincides with the red curve the half-life for mecillinam can be approximated at around
4 hours. B: MOPSgluRDM at 34◦C and pH 7.4. As the blue curve coincides with the
red curve the half-life for mecillinam is around 2 hours. C: MOPSgluRDM at 34◦ and
pH 6.5. Neither the blue nor the green curve reaches the red curve, therefore the half
life is greater than 6 hours. D, E: Raman spectroscopy confirms decreased degradation
of mecillinam in MOPSgluRDM at 34◦, pH 6.5. C: Raman spectra for the region
between 1000 and 1400 wavenumbers, recorded at times 0 to 47 hours (time in hours
indicated by colour as shown in the legend). Successive curves are shifted upwards for
clarity. The peak of interest is highlighted by the vertical black line. E: The relative
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peak height at 1278 cm−1 as a function of time is fit to an exponential decay, which
gives a half life of 7.8± 3.1 hours.The peak height at 1278 cm−1 was measured relative
to a stable portion of the Raman spectrum (1261 - 1266 cm−1)to remove any variations
due to changing background signals between timepoints.
S5 Fig. Delay time bioassay results for mecillinam in LB at 37◦ C and pH
7.
A: Bioassay measurements: growth curves for E. coli strain RJA002 in LB at pH 7.0,
37◦ C, for cultures inoculated at time zero (solid lines) and after a delay period of 2
hours (dashed lines). The different colours correspond to different (initial)
concentrations of mecillinam, as displayed in the legend, in µg/ml. B: Bioassay analysis
- the time T at which the growth curves reach an OD of 0.75 is plotted as a function of
the initial antibiotic concentration. The black data correspond to inoculation at time
zero; the blue data to inoculation after a 2 hour delay; the green data to inoculation
after a 4 hour delay; and the turquoise data to inoculation after a 6 hour delay. The red
line shows the black data, shifted by one unit on the log2 scale; since the green and
turquoise data fall onto the red line, the degradation half-life is between 4 and 6 hours.
In both panels A and B, the shaded areas represent the standard deviation between two
replicates.
S6 Fig. Growth curves for cefotaxime in MOPSgluRDM at 37◦ C and pH
7.
Regrowth is only observed in a narrow cefotaxime concentration range between 0.031
and 0.125µg/ml cefotaxime. Each curve is the average of 2-4 replicates and the shaded
areas represent the standard deviation. The blue curve (0.25 µg/ml Ctx.) shows
complete inhibition of growth over time, while the orange curve (0.016 µg/ml Ctx.)
shows no inhibition.
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